MENLO PARK, Calif., July 23, 2019 /PRNewswire/ — Ablacon Inc. announced today that it has entered into a $10 millionventure debt facility with Western Technology Investment (WTI). The debt is accompanied by a $2 million equity investment in the Company. This financing will help fund Ablacon’s first multicenter randomized clinical trial for Ablamap, an advanced mapping system for patients with atrial fibrillation.
Posts
Ablamap® System and Ablacath is FDA 510(k) cleared for use in the United States.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use for information on Indications, Contraindications, Warnings, Precautions and Adverse events.
Copyright © 2023 Ablacon, Inc.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use for information on Indications, Contraindications, Warnings, Precautions and Adverse events.
Copyright © 2023 Ablacon, Inc.